Bladder Cancer Weekly

March 16, 2026

Videos

Peer-to-Peer Clinical Conversations

ALBAN Trial Analysis: Evaluating Atezolizumab Addition to BCG Therapy in High-Risk, Non-Muscle-Invasive Bladder - Morgan Rouprêt

Morgan Rouprêt

Morgan Rouprêt discusses ALBAN trial results with Ashish Kamat.

View

SURE-02 Trial: A Patient-Driven, Bladder-Sparing Approach for MIBC - Andrea Necchi

Andrea Necchi

Elizabeth Plimack is joined by Andrea Necchi to discuss the SURE-02 trial, evaluating sacituzumab govitecan plus pembrolizumab in a bladder-sparing approach for muscle-invasive bladder cancer.

View

Beyond the Abstracts

Circulating Tumor DNA in Muscle-invasive Bladder Cancer: Promise, Pitfalls, and Path Forward - Beyond the Abstract

The Effect of Chronic Liver Disease on Adverse In-Hospital Outcomes After Radical Cystectomy and Ileal Conduit Urinary Diversion - Beyond the Abstract

Conference Coverage

EAU 2026: Final Analysis of the Phase 1 First-in-Human Study of an Erdafitinib Intravesical Drug-Releasing System in Patients with NMIBC Harboring Select FGFR Alterations

EAU 2026: Phase 1/2 Study of an Anti-PD-L1/IL-15 Variant Fusion Protein (SIM0237) in BCG Unresponsive High-Risk NMIBC

ASCO GU 2026: Quality of Care Measures Among Patients with Recurrent, Papillary-Only Bacillus Calmette–Guérin Experienced High-Risk Non–Muscle-Invasive Bladder Cancer

ASCO GU 2026: Outcomes with Subsequent Therapies Post-Enfortumab Vedotin/Pembrolizumab in Patients with Advanced Urothelial Carcinoma: Analysis of the UNITE Study

ASCO GU 2026: Real-world Use and Effectiveness of First-line Enfortumab Vedotin with Pembrolizumab in Patients with Advanced Urothelial Carcinoma in the US

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Refining prognostication in non-muscle-invasive bladder cancer: From clinical models to artificial intelligence.

Use of Artificial Intelligence Model Associated with Masson's Trichrome Staining as a Predictor of Muscle Invasion in Bladder Cancer.

Neoadjuvant immune checkpoint inhibitors for muscle-invasive urothelial carcinoma: a systematic review and meta-analysis.

Incorporating the Patient Voice into Attribute and Level Selection for a Preference Study: A Qualitative Study in Non-Muscle Invasive Bladder Cancer.

A Case of Unexpected Peritoneal Carcinomatosis From Colon Cancer Detected After Robot-Assisted Radical Cystectomy for Advanced Bladder Cancer.

Development and validation of a gemcitabine sensitivity-related long noncoding RNA signature for predicting the prognosis and subtypes of bladder cancer.

Impact of Surgical Wait Time on Survival After Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study.

For the First Time, Ferring Reports Revenue of over €2.5 Billion in 2025

Advances and challenges of PET imaging in bladder cancer-An update and future trends.

The changing landscape of urothelial carcinoma: on the edge of a paradigm shift.

Multi-omic profiling defines three distinct molecular subtypes of urothelial carcinoma with implications for precision therapy.

Research Progress on Financial Toxicity in Bladder Cancer Patients.

Comparative genomic landscape of primary and metastatic bladder urothelial carcinoma in a large-scale cohort.

Optimizing Oncological Outcomes in High-Grade Non-Muscle Invasive Bladder Cancer: The Impact of a Surgeon-Led Treatment Pathway - Beyond the Abstract

Management of Surgical Menopause in Female Patients with Bladder Cancer Undergoing Radical Cystectomy - Beyond the Abstract

Contemporary Practice Patterns in Female Radical Cystectomy: Results of a UK and Ireland Survey - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Bladder Cancer Weekly

Bladder Cancer

Login